Diabetes Research and Clinical Practice
Volume 64, Issue 1 , Pages 71-72 , April 2004

Sandostatin LAR for cystoid diabetic macular edema: a 1-year experience

  • Maria Concepcion Hernaez-Ortega

      Affiliations

    • European Innovative Biomedicine Institute (EIBI), C/Jardines 2, 1-G, 39700 Cantabria, Spain
    • Department of Ophthalmology, Hospital of Cruces, Vizcaya, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34-609409113.
    • ,
  • Enrique Soto-Pedre

      Affiliations

    • European Innovative Biomedicine Institute (EIBI), C/Jardines 2, 1-G, 39700 Cantabria, Spain
    • ,
  • Juan Jose Beitia Martin

      Affiliations

    • Endocrinology Section, Hospital of Galdacano, Vizcaya, Spain

Received 8 July 2003 ,Revised 3 October 2003 ,Accepted 7 October 2003.

References 

  1. Davis MI, Wilson SH, Grant MB. The therapeutic problem of proliferative diabetic retinopathy: targetting somatostatin receptors. Horm. Metab. Res. 2001;33:295–299
  2. Boehm BO, Lang GK, Jehle PM, Feldmann B, Lang GE. Octreotide reduces viteous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm. Metab. Res. 2001;33:300–306
  3. Kuijpers RW, Baarsma GS, Van Hagen PM. Treatment of cystoid macular edema with Octreotide. N. Engl. J. Med. 1998;338(9):624–626
  4. Van Hagen PM, Baarsma GS, Mooy CM. Somatostatin and somatostatin receptors in the retinal diseases. Eur. J. Endocrinol. 2000;143:S43–S51

PII: S0168-8227(03)00263-8

doi: 10.1016/j.diabres.2003.10.003

Diabetes Research and Clinical Practice
Volume 64, Issue 1 , Pages 71-72 , April 2004

Article Tools